ProMIS director buys 3,050 shares, adds warrants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.
Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrants to purchase Common Shares | 3,050 | $0.00 | $0.00 |
| Grant/Award | Common Shares | 3,050 | $12.13 | $37K |
| Holding | Common Shares | -- | -- | -- |
| Holding | Common Shares | -- | -- | -- |
Footnotes (3)
- F1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
- F2. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
- F3. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Patrick D. Kirwin report for ProMIS Neurosciences (PMN)?
What are the key terms of Patrick D. Kirwin’s ProMIS Neurosciences (PMN) warrants?
What is Patrick D. Kirwin’s relationship to ProMIS Neurosciences (PMN)?
AI-generated analysis. How Rhea-AI works. Not financial advice.